Chao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Zhang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Chuanbao Zhang
National Center for Clinical Laboratories, Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China
8 shared publications Ying Yan
National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beiijng, PR China
5 shared publicationsAixin Wang
National Center for Clinical Laboratories, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China
4 shared publicationsChuanbao Zhang
National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, P.R. China
3 shared publicationsXinyu Ye
National Center for Clinical Laboratories, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China
3 shared publicationsG.J. Mizejewski
Division of Translational Medicine, Molecular Diagnostics Laboratory, Wadsworth Center, New York State Department of Health, United States
2 shared publications
Latest Publications
- 27 April 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (4) , 479-491
Application of CAR-T therapy in solid tumors: current opportunities and challenges
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has achieved substantial progress in treating hematologic malignancies. However, its efficacy in solid tumors remains limited due to various biological and logistical challenges. This review systematically summarizes the advancements in CAR-T therapy for solid tumors, including lung cancer, pancreatic cancer, neuroblastoma, and breast cancer. It traces the progression of CAR-T cell design from the first to the fifth generation and explores the roles of key functional modules, such as scFv, hinge regions, and costimulatory domains. Major barriers to CAR-T application in solid tumors are discussed, including antigen heterogeneity, the lack of specific targets, CAR-T cell exhaustion, the immunosuppressive tumor microenvironment (TME), and physical barriers within tumor tissues. Additionally, the review highlights emerging strategies and recent developments from 2023 to 2025, such as bispecific and multispecific CAR-T cells, regional administration techniques, logic-gated CAR constructs, safety switches, and novel approaches to modulating the TME. Despite considerable challenges, the integration of these cutting-edge technologies is advancing CAR-T therapy for solid tumors, providing new prospects for patients with refractory solid malignancies. Finally, future directions for CAR-T applications in solid tumors are discussed.
- 27 April 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (4) , 479-491
Application of CAR-T therapy in solid tumors: current opportunities and challenges
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has achieved substantial progress in treating hematologic malignancies. However, its efficacy in solid tumors remains limited due to various biological and logistical challenges. This review systematically summarizes the advancements in CAR-T therapy for solid tumors, including lung cancer, pancreatic cancer, neuroblastoma, and breast cancer. It traces the progression of CAR-T cell design from the first to the fifth generation and explores the roles of key functional modules, such as scFv, hinge regions, and costimulatory domains. Major barriers to CAR-T application in solid tumors are discussed, including antigen heterogeneity, the lack of specific targets, CAR-T cell exhaustion, the immunosuppressive tumor microenvironment (TME), and physical barriers within tumor tissues. Additionally, the review highlights emerging strategies and recent developments from 2023 to 2025, such as bispecific and multispecific CAR-T cells, regional administration techniques, logic-gated CAR constructs, safety switches, and novel approaches to modulating the TME. Despite considerable challenges, the integration of these cutting-edge technologies is advancing CAR-T therapy for solid tumors, providing new prospects for patients with refractory solid malignancies. Finally, future directions for CAR-T applications in solid tumors are discussed.
- Open Access
- 6 April 2026
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 42 (1)
Mitochondrial dynamics and cancer: mechanisms and targeted therapy
Mitochondria, as key organelles in eukaryotic cells, regulate cellular energy homeostasis and functional integrity through dynamic processes, including fission, fusion, autophagy, and transport, underpinned by precise molecular mechanisms. In healthy cells, the equilibrium of mitochondrial dynamics ensures network quality control and metabolic coordination. In contrast, cancer cells exhibit multi-dimensional dysregulation characterized by hyperactive fission, impaired fusion, and compensatory upregulation of respiratory chain assembly factors, creating a state of “morphology-function decoupling”. These alterations drive tumor progression by reprogramming cellular metabolism, promoting proliferation, inhibiting apoptosis, enhancing migration and drug resistance, and facilitating immune evasion. This review elucidates the molecular mechanisms underlying mitochondrial dynamics, their dysregulation in cancer, and their influence on tumor behavior, while also addressing the core challenges of current targeted therapeutic strategies and the novel therapeutic paradigm of “network remodeling”, offering new insights into tumor biology and precision cancer therapy. Graphical Abstract
- 6 April 2026
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 42 (1)
Open AccessMitochondrial dynamics and cancer: mechanisms and targeted therapy
Mitochondria, as key organelles in eukaryotic cells, regulate cellular energy homeostasis and functional integrity through dynamic processes, including fission, fusion, autophagy, and transport, underpinned by precise molecular mechanisms. In healthy cells, the equilibrium of mitochondrial dynamics ensures network quality control and metabolic coordination. In contrast, cancer cells exhibit multi-dimensional dysregulation characterized by hyperactive fission, impaired fusion, and compensatory upregulation of respiratory chain assembly factors, creating a state of “morphology-function decoupling”. These alterations drive tumor progression by reprogramming cellular metabolism, promoting proliferation, inhibiting apoptosis, enhancing migration and drug resistance, and facilitating immune evasion. This review elucidates the molecular mechanisms underlying mitochondrial dynamics, their dysregulation in cancer, and their influence on tumor behavior, while also addressing the core challenges of current targeted therapeutic strategies and the novel therapeutic paradigm of “network remodeling”, offering new insights into tumor biology and precision cancer therapy. Graphical Abstract
- 23 June 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 577, 120446
Urinary iodine testing practices in China: Results of the 5-year external quality assessment program
- 23 June 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 577, 120446
Urinary iodine testing practices in China: Results of the 5-year external quality assessment program
- 14 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125824
Mechanisms of GIP in inhibiting cancer growth: Updates and perspectives
- 14 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125824
Mechanisms of GIP in inhibiting cancer growth: Updates and perspectives
- 27 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177554
Growth inhibitory peptides: a potential novel therapeutic approach to cancer treatment
- 27 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177554
Growth inhibitory peptides: a potential novel therapeutic approach to cancer treatment
- 18 November 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 62 (3) , 155-164
Coefficients of variation analyses of internal quality control status for blood lead in China from 2015 to 2023
Background: Blood lead test is widely conducted in Chinese laboratories, while the imprecision of blood lead measurement based on internal quality control (IQC) across China has not been comprehensively evaluated nowadays. Methods: Using the IQC data of blood lead collected through a web-based external quality assessment (EQA) reporting system, we analysed current coefficients of variation (CVs) of blood lead from 2015 to 2023 among Chinese laboratories. Two allowable total error (TEa) imprecision levels from EQA were applied to calculate the pass rates, namely percentages of laboratories meeting precision quality specifications. Besides, CV values and pass rates by different subgroups were further performed to assess potential differences. Results: Generally, median CV values significantly declined year by year from 6.8% in February 2015 to 5.9% in March 2023. The pass rates based on 1/3 TEa showed upward trends increasing from 15.3% in February 2015 to 20.0% in March 2023, but these percentages were non-ideal with less than 25%. No significant differences in CVs were found between tertiary hospitals and non-tertiary hospitals and between accredited and non-accredited laboratories. Significant time trends were observed in tertiary hospitals and non-accredited laboratories. As for manufacturers, Bohui and self-made QC sample were most widely used with obvious interannual declining trends of CVs. Conclusions: The CVs of blood lead demonstrated continuous overall improvements in the past twenty years. However, relatively lower pass rates indicated the non-ideal imprecision performance, and more proper performance specifications are warranted. Thus, imprecision improvement and ongoing investigation for blood lead IQC are still needed.
- 18 November 2024
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 62 (3) , 155-164
Coefficients of variation analyses of internal quality control status for blood lead in China from 2015 to 2023
Background: Blood lead test is widely conducted in Chinese laboratories, while the imprecision of blood lead measurement based on internal quality control (IQC) across China has not been comprehensively evaluated nowadays. Methods: Using the IQC data of blood lead collected through a web-based external quality assessment (EQA) reporting system, we analysed current coefficients of variation (CVs) of blood lead from 2015 to 2023 among Chinese laboratories. Two allowable total error (TEa) imprecision levels from EQA were applied to calculate the pass rates, namely percentages of laboratories meeting precision quality specifications. Besides, CV values and pass rates by different subgroups were further performed to assess potential differences. Results: Generally, median CV values significantly declined year by year from 6.8% in February 2015 to 5.9% in March 2023. The pass rates based on 1/3 TEa showed upward trends increasing from 15.3% in February 2015 to 20.0% in March 2023, but these percentages were non-ideal with less than 25%. No significant differences in CVs were found between tertiary hospitals and non-tertiary hospitals and between accredited and non-accredited laboratories. Significant time trends were observed in tertiary hospitals and non-accredited laboratories. As for manufacturers, Bohui and self-made QC sample were most widely used with obvious interannual declining trends of CVs. Conclusions: The CVs of blood lead demonstrated continuous overall improvements in the past twenty years. However, relatively lower pass rates indicated the non-ideal imprecision performance, and more proper performance specifications are warranted. Thus, imprecision improvement and ongoing investigation for blood lead IQC are still needed.
- 16 January 2024
- Published by Springer Nature in Neurochemical Research
- Vol. 49 (4) , 834-846
The Role of IL-6 in Neurodegenerative Disorders
“Neurodegenerative disorder” is an umbrella term for a group of fatal progressive neurological illnesses characterized by neuronal loss and inflammation. Interleukin-6 (IL-6), a pleiotropic cytokine, significantly affects the activities of nerve cells and plays a pivotal role in neuroinflammation. Furthermore, as high levels of IL-6 have been frequently observed in association with several neurodegenerative disorders, it may potentially be used as a biomarker for the progression and prognosis of these diseases. This review summarizes the production and function of IL-6 as well as its downstream signaling pathways. Moreover, we make a comprehensive review on the roles of IL-6 in neurodegenerative disorders and its potential clinical application.
- 16 January 2024
- Published by Springer Nature in Neurochemical Research
- Vol. 49 (4) , 834-846
The Role of IL-6 in Neurodegenerative Disorders
“Neurodegenerative disorder” is an umbrella term for a group of fatal progressive neurological illnesses characterized by neuronal loss and inflammation. Interleukin-6 (IL-6), a pleiotropic cytokine, significantly affects the activities of nerve cells and plays a pivotal role in neuroinflammation. Furthermore, as high levels of IL-6 have been frequently observed in association with several neurodegenerative disorders, it may potentially be used as a biomarker for the progression and prognosis of these diseases. This review summarizes the production and function of IL-6 as well as its downstream signaling pathways. Moreover, we make a comprehensive review on the roles of IL-6 in neurodegenerative disorders and its potential clinical application.
- 7 April 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 544, 117331
Evaluation of blood lead measurements by the 6-year external quality assessment program in China
- 7 April 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 544, 117331
Evaluation of blood lead measurements by the 6-year external quality assessment program in China
- Open Access
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 345-354
An Accurate Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry Method for Serum C-Peptide and Its Use in Harmonization in China
Yuhang Deng, M.D., Chao Zhang, M.D., Jing Wang, M.M., Jie Zeng, M.M., Jiangtao Zhang, M.M., Tianjiao Zhang, M.D., Haijian Zhao, M.M., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2023;43:345-54. https://doi.org/10.3343/alm.2023.43.4.345
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 345-354
Open AccessAn Accurate Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry Method for Serum C-Peptide and Its Use in Harmonization in China
Yuhang Deng, M.D., Chao Zhang, M.D., Jing Wang, M.M., Jie Zeng, M.M., Jiangtao Zhang, M.M., Tianjiao Zhang, M.D., Haijian Zhao, M.M., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2023;43:345-54. https://doi.org/10.3343/alm.2023.43.4.345